Alessandro Doria
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Alessandro Doria sits in the upper quartile of US sponsors by registered trial count (#3,663 of 15,742 sponsors by registered trial count).
Alessandro Doria: 3 sponsored US clinical trials, 1 recruiting.
Alessandro Doria sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetic Nephropathies, with 2 trials.
Upper-quartile sponsor footprint
Alessandro Doria sits in the upper quartile of the sponsor corpus (#3,663 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
NCT06217302
A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes
NCT04929379
A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
NCT02017171
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
Where Alessandro Doria enrollment is open (later-stage tilt)
1 recruiting of 3 indexed (33% open); 1 completed (33%).
Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Diabetic Nephropathies (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alessandro Doria: open-pipeline peers nationwide
Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Alessandro Doria sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Alessandro Doria page
3 registered trials is a research-attention snapshot, not an endorsement of Alessandro Doria or any single study.
- 1 of Alessandro Doria's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetic Nephropathies is the condition Alessandro Doria studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Nephropathies trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Alessandro Doria pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.